menu
    • menu
    [{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Karolinska Institutet","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biologics \/ Karolinska Institutet"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Cobra Biologics \/ AstraZeneca"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene AB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"DNA plasmids","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ CombiGene AB","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ CombiGene AB"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CG01","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cobra Biologics \/ Cobra Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biologics \/ Cobra Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Cobra Biologics

    Menu

    Cobra Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : CombiGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cobra Biologics Completes Production of Master Cell Banks for CombiGene’s Epilepsy Gene Therapy Drug Candida...

                            Details : Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.

                            Brand Name : CG01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 18, 2020

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : CombiGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNA plasmids

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : CombiGene AB

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate

                            Details : Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.

                            Brand Name : CG01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 13, 2020

                            Lead Product(s) : DNA plasmids

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : CombiGene AB

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD1222

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate

                            Details : Cobra will provide Astrazenrca with GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

                            Brand Name : AZD1222

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 16, 2020

                            Lead Product(s) : AZD1222

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project

                            Details : Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 02, 2020

                            Lead Product(s) : CG01

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed

                            Cobra Biologics

                            United Kingdom arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNA vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Karolinska Institutet

                            Deal Size : $3.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

                            Details : The funding will leverage phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 31, 2020

                            Lead Product(s) : DNA vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Karolinska Institutet

                            Deal Size : $3.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth